{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T07:54:15Z","timestamp":1772697255566,"version":"3.50.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021954","name":"Tour de Cure","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chemotherapy remains the standard of care for metastatic soft tissue sarcoma (STS), but clinical benefit is modest. Immune checkpoint inhibitors (ICIs), such as anti-programmed cell death 1 (PD-1) and anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4), have transformed cancer treatment, yet their efficacy in STS is variable and largely confined to undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (LPS). Reliable biomarkers to predict ICI response in STS are understudied and currently lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We examined mutation profiles and analysed longitudinal blood samples from STS patients (n=13) treated with anti-PD-1\/PD-L1\u2013based therapy to identify molecular features and circulating immune correlates of ICI efficacy. To gain deeper insight, single-cell RNA sequencing was performed on peripheral blood mononuclear cells (PBMCs) from a patient with prolonged stable disease (&amp;gt;6 months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Complete blood counts and PBMC profiling demonstrated that elevated circulating lymphoid cells were associated with response, whereas enrichment of innate immune populations, particularly neutrophils and monocytes, correlated with non-response. Single-cell RNA sequencing of PBMCs from a patient with prolonged stable disease revealed dynamic shifts in monocyte and CD8 T cell phenotypes and inflammatory signalling pathways, which paralleled radiological tumour regression and subsequent progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our findings highlight peripheral immune profiles as candidate biomarkers for predicting and monitoring ICI efficacy in STS. Incorporating these immune markers could refine patient selection, reduce unnecessary toxicity, and support adaptive treatment strategies for patients with this rare and heterogenous cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1783216","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T06:55:14Z","timestamp":1772693714000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Distinct immunologic patterns of response and resistance to anti-PD-1\/PD-L1-based immunotherapy in patients with soft tissue sarcoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Brie-Anne","family":"Mannah","sequence":"first","affiliation":[{"name":"Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University","place":["Sydney, NSW, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Yang","sequence":"additional","affiliation":[{"name":"Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University","place":["Sydney, NSW, Australia"]},{"name":"Melanoma Institute Australia, The University of Sydney","place":["Sydney, NSW, Australia"]},{"name":"School of Mathematics and Statistics, The University of Sydney","place":["Sydney, NSW, Australia"]},{"name":"Sydney Precision Data Science Centre, The University of Sydney","place":["Sydney, NSW, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijia","family":"Yu","sequence":"additional","affiliation":[{"name":"School of Mathematics and Statistics, The University of Sydney","place":["Sydney, NSW, Australia"]},{"name":"Sydney Precision Data Science Centre, The University of Sydney","place":["Sydney, NSW, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Gurney","sequence":"additional","affiliation":[{"name":"Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University","place":["Sydney, NSW, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Y. H.","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Mathematics and Statistics, The University of Sydney","place":["Sydney, NSW, Australia"]},{"name":"Sydney Precision Data Science Centre, The University of Sydney","place":["Sydney, NSW, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Park","sequence":"additional","affiliation":[{"name":"Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University","place":["Sydney, NSW, Australia"]},{"name":"Nepean Cancer and Wellness Centre, Nepean Hospital","place":["Sydney, NSW, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su Yin","family":"Lim","sequence":"additional","affiliation":[{"name":"Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University","place":["Sydney, NSW, Australia"]},{"name":"Melanoma Institute Australia, The University of Sydney","place":["Sydney, NSW, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_205423","article-title":"More than 50 subtypes of soft tissue sarcoma: paving the path for histology-driven treatments","volume":"38","author":"Katz","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1199292","article-title":"Chemotherapeutic drugs for soft tissue sarcomas: a review","volume":"14","author":"Tian","year":"2023","journal-title":"Front Pharmacol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score >\/= 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"168145","DOI":"10.1155\/2013\/168145","article-title":"A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma","volume":"2013","author":"Maki","year":"2013","journal-title":"Sarcoma"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0491","article-title":"Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors","volume":"22","author":"Merchant","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.11015","article-title":"Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated\/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts","volume":"37","author":"Burgess","year":"2019","journal-title":"Am Soc Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D\u2019Angelo","year":"2018","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35477","article-title":"Blood-based biomarkers in soft tissue sarcoma: Implications for immune checkpoint inhibitor therapy","volume":"157","author":"Mannah","year":"2025","journal-title":"Int J Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btw777","article-title":"Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R","volume":"33","author":"McCarthy","year":"2017","journal-title":"Bioinformatics"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20199389","article-title":"scClassify: sample size estimation and multiscale classification of cells using single and multiple reference","volume":"16","author":"Lin","year":"2020","journal-title":"Mol Syst Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0465-8","article-title":"Systematic comparison of single-cell and single-nucleus RNA-sequencing methods","volume":"38","author":"Ding","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1016\/j.cell.2025.02.017","article-title":"Asian diversity in human immune cells","volume":"188","author":"Kock","year":"2025","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btac590","article-title":"scFeatures: multi-view representations of single-cell and spatial data for disease outcome prediction","volume":"38","author":"Cao","year":"2022","journal-title":"Bioinformatics"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nature08460","article-title":"Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1","volume":"462","author":"Barbie","year":"2009","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1082084","article-title":"Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cells","volume":"13","author":"Gazzano","year":"2022","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.59125","article-title":"Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients","volume":"3","author":"Osa","year":"2018","journal-title":"JCI Insight"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltad001","article-title":"Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood","volume":"3","author":"Edner","year":"2023","journal-title":"Immunother Adv"},{"key":"B23","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","article-title":"Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors","volume":"12","author":"Valero","year":"2021","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3610038","DOI":"10.1155\/2022\/3610038","article-title":"Prognostic value of lymphocyte-to-monocyte ratio (LMR) in cancer patients undergoing immune checkpoint inhibitors","volume":"2022","author":"Wan","year":"2022","journal-title":"Dis Mark"},{"key":"B25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40364-023-00513-5","article-title":"Biomarkers for immune checkpoint inhibition in sarcomas - are we close to clinical implementation","volume":"11","author":"Yiong","year":"2023","journal-title":"biomark Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1824","article-title":"Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab","volume":"26","author":"Keung","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01310","article-title":"Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors","volume":"9","author":"Weber","year":"2018","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01590","article-title":"Myeloid cells as clinical biomarkers for immune checkpoint blockade","volume":"11","author":"Peranzoni","year":"2020","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.3390\/diagnostics12061408","article-title":"Circulating lymphocytes reflect the local immune response in patients with colorectal carcinoma","volume":"12","author":"Waidhauser","year":"2022","journal-title":"Diagn (Basel)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2021.12473","article-title":"Immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma","volume":"21","author":"Kim","year":"2021","journal-title":"Oncol Lett"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2019.08.005","article-title":"Significance of TIM3 expression in cancer: From biology to the clinic","volume":"46","author":"Solinas","year":"2019","journal-title":"Semin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J Exp Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1200778","article-title":"Tumor-infiltrating Tim-3(+) T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk","volume":"5","author":"Li","year":"2016","journal-title":"Oncoimmunology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-3-S2-P196","article-title":"PD-1 blockade upregulate TIM-3 expression as a compensatory regulation of immune check point receptors in HNSCC TIL","volume":"3","author":"Shayan","year":"2015","journal-title":"J ImmunoTher Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1261779","article-title":"Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer","volume":"6","author":"Shayan","year":"2017","journal-title":"Oncoimmunology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.654749","article-title":"Targeting STAT3 abrogates tim-3 upregulation of adaptive resistance to PD-1 blockade on regulatory T cells of melanoma","volume":"12","author":"Huang","year":"2021","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4746","article-title":"Phase I\/ib clinical trial of sabatolimab, an anti-TIM-3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors","volume":"27","author":"Curigliano","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-0884","article-title":"Combined targeting of PD-1 and TIM-3 in patients with locally advanced or metastatic melanoma: AMBER cohorts 1c, 1e, and 2A","volume":"31","author":"Davar","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1101497","article-title":"Nonclassical monocytes potentiate anti-tumoral CD8(+) T cell responses in the lungs","volume":"14","author":"Padgett","year":"2023","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16784","article-title":"Non-classical monocytes enhance the efficacy of immune checkpoint inhibitors on colon cancer in a syngeneic mouse model","volume":"44","author":"Goshima","year":"2024","journal-title":"Anticancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8512","article-title":"Terminally differentiated CD8(+) T cells and CD57(-)FOXP3(+)CD8(+) T cells are highly associated with the efficacy of immunotherapy using activated autologous lymphocytes","volume":"15","author":"Akagi","year":"2018","journal-title":"Oncol Lett"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1783216\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T06:55:15Z","timestamp":1772693715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1783216\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2026.1783216"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1783216","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"article-number":"1783216"}}